Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
| Revenue (TTM) | $72.25B |
| Gross Profit (TTM) | $59.85B |
| EBITDA | $36.22B |
| Operating Margin | 49.40% |
| Return on Equity | 107.50% |
| Return on Assets | 20.70% |
| Revenue/Share (TTM) | $80.61 |
| Book Value | $34.92 |
| Price-to-Book | 34.23 |
| Price-to-Sales (TTM) | 15.07 |
| EV/Revenue | 15.31 |
| EV/EBITDA | 30.54 |
| Quarterly Earnings Growth (YoY) | 169.90% |
| Quarterly Revenue Growth (YoY) | 55.50% |
| Shares Outstanding | $891.74M |
| Float | $889.33M |
| % Insiders | 0.15% |
| % Institutions | 85.12% |
Volatility is currently contracting
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1 franchise.
Eli Lilly (NYSE:LLY | LLY Price Prediction) has accelerated despite its $1 trillion scale.
Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.
The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.
Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.
Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry between the two groups.
Analysts have suggested retatrutide could become a blockbuster weight loss drug if approved. In January, TD Cowen analysts estimated retatrutide could generate $3.8 billion in sales in 2030, while GlobalData forecasts sales of $15.6 billion by 2031.
Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.
Eli Lilly on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit an application to the U.S. Food and Drug Administration in the first quarter of next year.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LLY and any ticker you trade — then tracks every position and per-strategy win rate.
